tradingkey.logo

India's Medicamen Biotech gains on US FDA nod for blood cancer drug

ReutersJun 3, 2025 9:40 AM

Shares of Medicamen Biotech MEBI.NS rise 4% to 434.95 rupees

Drugmaker gets U.S. FDA approval for Bortezomib injection 3.5 mg

Bortezomib therapeutically equivalent to Takeda's 4502.T blood cancer drug Velcade

More than 49,576 shares traded, 2.1x 30-day moving avg

Stock trims YTD losses to ~3%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI